<DOC>
	<DOCNO>NCT01369641</DOCNO>
	<brief_summary>This pilot , randomize , self-controlled study effect intratympanic sodium thiosulfate ( STS ) degree hear loss patient receive cisplatin therapy . Sodium thiosulfate inactive ingredient contain sulfacetamide ophthalmic solution use routinely otic solution deliver middle ear space . The hypothesis study local administration sodium thiosulfate ( STS ) result improve hearing compare ear receive study drug patient receive systemic cisplatin therapy .</brief_summary>
	<brief_title>The Effect Sodium Thiosulfate Eardrops Hearing Loss Patients Who Receive Cisplatin Therapy</brief_title>
	<detailed_description>Platinum-based chemotherapeutic agent use treat number malignant tumor , child adult . Examples tumor include : osteosarcoma , Wilms ' tumor , rhabdomyosarcoma , neuroblastoma , Ewing 's sarcoma , primary brain tumor , carcinoma , various solid tumor . Cisplatin associate dose-dependent , high frequency sensorineural hearing loss . With increase dos , hear loss worsens include speech frequency . Vestibular function also damage platinum-based toxicity . Cisplatin cause ototoxicity formation reactive oxygen specie activation apoptotic pathway outer hair cell stria vascularis . Rates ototoxicity approximately 80 % audiologic finding hear loss , 20 % symptomatic hearing loss . These number higher receive high dose cisplatin , child , prior irradiation prior hearing loss . A number agent investigate animal model otoprotection toxic effect cis- carboplatin . Among , sodium thiosulfate ( STS ) show particular promise otoprotective agent . STS approve US Food Drug Administration ( FDA ) antidote cyanide nitroprusside toxicity calciphylaxis . STS show act antioxidant well chelate agent vivo . The chelate property sulfur-thiol functional group believe responsible otoprotective effect STS , binding , inactivate platinum . The thiol compound may also act scavenge reactive oxygen specie produce platinum , thus prevent initiation apoptotic pathway . Several study demonstrate otoprotective effect intravenous STS animal model . Subsequent study show similar benefit STS administer intravenously human . A major drawback mode delivery , however , fear reduces anti-tumor activity platinum . Sodium thiosulfate believe bind cisplatin , form complex excrete kidney . Though may decrease ototoxicity associate platinum , may also decrease anti-neoplastic property agent . There conflict report reduce tumoricidal property STS vitro , though vivo study suggest adverse effect vivo . In view potential systemic STS reduce tumoricidal effect platinum agent , researcher seek alternate mode delivery . Recent animal study examine effect sodium thiosulfate deliver locally middle ear space . Stocks , et al demonstrate otoprotective effect STS deliver middle ear space guinea pig . Wang , et al show complete prevention ototoxic effect cisplatin guinea pig treat round window application STS . In study , compound action potential ( CAP ) distortion product otoacoustic emission ( DPOAE ) unchanged , out hair cell ( OHC ) inner hair cell ( IHC ) preserve . This effect , however , demonstrate similar study Wimmer , et al . The temporal spatial separation platinum STS animal study prompt Zuur colleague state , `` future , may desirable examine additional possibility two-route administration scheme chemotherapy otoprotective drug human . '' There study date intratympanic sodium thiosulfate human .</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>1 . Adults receive cisplatin therapy dose range 80120mg/m2 2 . Subjects capable give informed consent , appropriate , acceptable surrogate capable give consent subject 's behalf . 1 . Subjects active middle ear disease ( unilateral bilateral ) 2 . Subjects prior treatment platinumbased chemotherapeutic agent ototoxic agent 3 . Subjects allergy sodium thiosulfate 4 . Subjects tumor involve cranial nerve VIII 5 . Subjects preexist absence otoacoustic emission ( unilateral bilateral ) 6 . Subjects 5 dB interaural difference puretone threshold initial audiometric screen 7 . Chronic use know ototoxic agent ( e.g . furosemide , aminoglycosides , etc ) 8 . Subjects history prior irradiation head neck .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cisplatin</keyword>
	<keyword>STS</keyword>
	<keyword>sodium thiosulfate</keyword>
	<keyword>Adults</keyword>
	<keyword>dose range 80-120mg/m2</keyword>
</DOC>